<DOC>
	<DOCNO>NCT01910402</DOCNO>
	<brief_summary>This study design demonstrate non-inferior antiviral activity DTG/ABC/3TC fix dose combination ( FDC ) daily ( OD ) compare atazanavir plus ritonavir ( ATV+RTV ) tenofovir disoproxil fumarate/emtricitabine fix dose combination ( TDF/FTC FDC ) OD HIV-1 infect , ART-naïve woman 48 week . This study also characterize safety tolerability DTG/ABC/3TC FDC compare ATV+RTV+TDF/FTC FDC . Sufficient number subject screen order ensure total approximately 474 subject randomize ( 237 study arm )</brief_summary>
	<brief_title>A Study Determine Safety Efficacy Dolutegravir/Abacavir/Lamivudine ( DTG/ABC/3TC ) Human Immunodeficiency Virus ( HIV ) -1 Infected Antiretroviral Therapy ( ART ) Naïve Women ( ARIA )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>HIV1 infect female ( gender birth ) &gt; =18 year age Women capable become pregnant must use appropriate contraception study ( define protocol ) HIV1 infection document Screening plasma HIV1 RNA &gt; =500 c/mL . Documentation subject negative HLAB*5701 allele . Antiretroviralnaïve ( &lt; =10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection ) . Signed date write informed consent obtain subject subject 's legal representative prior screen . Women pregnant breastfeed Women plan become pregnant first 48 week study Any subject medical intervention gender reassignment Any evidence active Centers Disease Control Prevention ( CDC ) Category C disease Subjects degree hepatic impairment Subjects positive hepatitis B Screening , anticipate need HCV therapy study History presence allergy study drug component drug class Ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous cell carcinoma , cervical intraepithelial neoplasia pose significant suicidality risk History osteoporosis fracture require pharmacologic therapy Treatment HIV1 immunotherapeutic vaccine within 90 day Screening Treatment follow agent within 28 day Screening : radiation therapy ; cytotoxic chemotherapeutic agent ; immunomodulators alter immune response ; Treatment agent , document activity HIV1 vitro within 28 day first dose investigational product ( IP ) Exposure experimental drug experimental vaccine within either 28 day , 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose IP Any evidence primary viral resistance base presence major resistanceassociated mutation Screening result , know , historical resistance test result Any verify Grade 4 laboratory abnormality , exception Grade 4 lipid abnormality ( total cholesterol , triglyceride , High Density Lipoprotein ( HDL ) cholesterol , Low Density Lipoprotein ( LDL ) cholesterol ) Any acute laboratory abnormality Screening , , opinion Investigator , would preclude subject 's participation study investigational compound Alanine aminotransferase ( ALT ) ≥5 time upper limit normal ( ULN ) , ALT ≥ 3xULN bilirubin ≥ 1.5xULN ( &gt; 35 % direct bilirubin ) Subject CrCL &lt; 50 mL/min via CockroftGault method Corrected QT interval ( QTc ( Bazett ) ) ≥450msec QTc ( Bazett ) ≥480msec subject bundle branch block .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>antiretroviral therapy naïve</keyword>
	<keyword>woman</keyword>
	<keyword>daily</keyword>
	<keyword>HIV infection</keyword>
	<keyword>atazanavir</keyword>
	<keyword>tenofovir/emtricitabine</keyword>
	<keyword>dolutegravir/abacavir/lamivudine fix dose combination</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>ritonavir</keyword>
</DOC>